Tcfap2c acts as a key factor in mammary tumorigenesis

 

The molecular variation of breast cancer subtypes is complex and is defined by characteristic patterns of gene expression, which influence its response to gene therapy. TFAP2C/AP-2γ has been reported as a key factor in development of the mammary gland, as well as in regulation of gene expression of one of the subtype of breast cancer with HER2-amplification. In this study, Park et al. conducted a serious experiments to gain greater insight into functions of TFAP2C on mammary tumorigeneisis in MMTV-Neu transgenic female mice. The article was published in Oncogene, recently.

 

By administrating conditional knockout (KO) of Tcfap2c, researchers found the loss of Tcfap2c in MMTV-Neu transgenic female mice reduced tumor cell proliferation and Egfr levels, meanwhile increased latency of tumorigenesis and tumor cell apoptosis. For a further investigation on factors related to TCFAP2, they established MMneu-flAP2C cell line, derived from MMTV-Neu/Tcfap2c^L/L control animals and cell lines with and without Tcfap2c, created by adenovirus-mediated transduction. a reduction of cell viability and Egfr expression were also found in this in vitro experiment. Furthermore, they found decreased viability of mammary tumor cells was directly related to impaired function of Egfr, which is targeted by Tcfap2 in murine. These findings suggest an important role of Tcfap2c in mammary tumorigenesis and reveal an in-depth view of EGFR pathway in breast cancer.

 

Reference:
Oncogene. 2015 Mar 16. doi: 10.1038/onc.2015.59.

Related Products

Cat.No.	Product Name	Information
S1079	PD153035 HCl	PD153035 HCl (SU-5271 HCl, AG1517 HCl, ZM 252868 HCl) is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM in cell-free assays; little effect noted against PGDFR, FGFR, CSF-1, InsR and Src.

Related Targets

EGFR